HomeCompareSSUMY vs PFE

SSUMY vs PFE: Dividend Comparison 2026

SSUMY yields 1.15% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SSUMY wins by $19.9K in total portfolio value
10 years
SSUMY
SSUMY
● Live price
1.15%
Share price
$39.10
Annual div
$0.45
5Y div CAGR
54.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.4K
Annual income
$21,405.82
Full SSUMY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SSUMY vs PFE

📍 SSUMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSUMYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSUMY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSUMY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSUMY
Annual income on $10K today (after 15% tax)
$98.03/yr
After 10yr DRIP, annual income (after tax)
$18,194.95/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $4,124.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSUMY + PFE for your $10,000?

SSUMY: 50%PFE: 50%
100% PFE50/50100% SSUMY
Portfolio after 10yr
$59.5K
Annual income
$23,832.27/yr
Blended yield
40.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SSUMY
No analyst data
Altman Z
1.7
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSUMY buys
0
PFE buys
0
No recent congressional trades found for SSUMY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSUMYPFE
Forward yield1.15%6.13%
Annual dividend / share$0.45$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR54.2%13.2%
Portfolio after 10y$69.4K$49.6K
Annual income after 10y$21,405.82$26,258.71
Total dividends collected$45.5K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SSUMY vs PFE ($10,000, DRIP)

YearSSUMY PortfolioSSUMY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,878$177.84$9,153$693.39+$1.7KSSUMY
2$11,918$278.79$8,593$849.25+$3.3KSSUMY
3$13,193$440.19$8,336$1,066.78+$4.9KSSUMY
4$14,818$702.21$8,437$1,384.80+$6.4KSSUMY
5$16,992$1,136.67$9,013$1,875.40+$8.0KSSUMY
6$20,060$1,878.40$10,306$2,680.72+$9.8KSSUMY
7$24,660$3,195.74$12,820$4,101.38+$11.8KSSUMY
8$32,048$5,661.52$17,673$6,826.70+$14.4KSSUMY
9$44,894$10,603.21$27,543$12,591.86+$17.4KSSUMY
10$69,443$21,405.82$49,560$26,258.71+$19.9KSSUMY

SSUMY vs PFE: Complete Analysis 2026

SSUMYStock

Sumitomo Corporation engages in general trading business worldwide. It operates through six segments: Metal Products; Transportation & Construction Systems; Infrastructure; Media & Digital; Living Related & Real Estate; and Mineral Resources, Energy, Chemical & Electronics. The company provides steel sheets and tubular products; and manufactures, leases, sells, services, and finances ships, aircrafts, motor vehicles, construction equipment, and components and parts. It is also involved in the development of renewable energy projects comprising power generation and power plant engineering, procurement, and construction activities; electricity retail; industrial facilities and equipment, water, transportation systems and infrastructure, airports, smart city project, environmental solutions, and storage battery businesses; development and operation of industrial parks; arranging insurance; and provision of logistics services. In addition, the company engages in the cable television, 5G related technologies, programming distribution, movies, digital media and video content, TV shopping, and e-commerce businesses; cell phone, ICT platform, digital solution, and venture capital businesses; provision of smart communications infrastructure; operation of food supermarkets and drugstore chains; trade of cement and building materials; and real estate businesses. Further, it develops and trades in coal, iron ore, manganese, uranium, non-ferrous and precious metals, petroleum, natural gas and liquefied natural gas, and commodity derivative transactions; trades in non-ferrous metal products, liquefied petroleum gas, storage batteries, carbon products, plastics, organic and inorganic chemicals, silicon wafers, LEDs, pharmaceuticals, agricultural chemicals, household insecticides, fertilizers, and veterinary drugs; engages in the investing activities; and provides electronics manufacturing services. The company was incorporated in 1919 and is headquartered in Tokyo, Japan.

Full SSUMY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SSUMY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSUMY vs SCHDSSUMY vs JEPISSUMY vs OSSUMY vs KOSSUMY vs MAINSSUMY vs JNJSSUMY vs MRKSSUMY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.